COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 1, 2003, Pages 67-70

  Ray, Wayne A ^a   Macdonald, Thomas M ^b   Solomon, Daniel H ^c   Graham, David J ^d   Avorn, Jerry ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DICLOFENAC; GROWTH FACTOR; IBUPROFEN; ISOENZYME; LIPOPOLYSACCHARIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL ESTER; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENZYME ACTIVITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IC 50; INTESTINE PERFORATION; ISCHEMIC HEART DISEASE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 0037272711     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.798     Document Type: Article

References (20)

1. Bombardier C, Laine L, Reicein A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
2. Topper JN, Cai J, Falb D, Gimbrone MA, Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 10417-10422.
3. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102(8): 840-845.
4. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002; 39: 521-522.
5. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
6. Yamamoto T, Kakar NR, Vina ER, Johnson PE, Bing RJ. Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. Pharmacology 2001; 63: 28-33.
7. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 2000; 97: 0197-10202.
8. Saito T, Rodger IW, Hu F, Shennib H, Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772-775.
9. Patel HH, Gross GJ. The disputed role of COX-2 in myocardial infarction, is the jury still out? J Mol Cell Cardiol 2002; 34: 1-3.
10. Camitta MG, Gabel SA, Chulada P, et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001; 104: 2453-2458.
11. Clement R, Das DK, Engelman RM, et al. Role of a nonsteroidal anti-inflammatory agent, ibuprofen, in coronary revascularization after acute myocardial infarction. Basic Res Cardiol 1990; 85: 55-70.
12. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-484.
13. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Intern Med 2000; 160: 777-784.
14. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
15. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104.
16. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359(9301): 118-123.
17. Cardiovascular safety review Rofecoxib http://www.fda.gov/ ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf
18. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Submitted.
19. MacDonald TM, Pettitt D, Goldstein J, Burke TJ, Zhao S, Morant SV. The risks of upper gastrointestinal haemorrhage (UGIH) in users of meloxicam, cyclooxygenase-2 (COX-2) specific inhibitors and other nonsteroidal anti-inflammatory drugs (NSAIDs presented at ICPE August, 2002, Edinburgh. Pharmacoepi Drug Saf 2002; 11: S12.
20. Ray WA, Stein CM, Daugherty JR, Hall K, Griffin MR. COX-2 selective NSAIDs and the risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.